Pfizer today said it is seeking an amended emergency use authorization for its COVID-19 vaccine, requesting that the Food and Drug Administration allow its use for individuals between 12 and 15 years old.

The request follows last week’s release of late-trial data affirming the vaccine’s safety for that age group, along with 100% effectiveness in preventing COVID-19.

Related News Articles

Headline
In this AHA video for Mother’s Day, part of AHA’s #MyWhy social media campaign, a pregnant health care worker explains why she chose to get…
Headline
Moderna Inc. told investors today that is intends to soon file for full Food and Drug Administration approval for its COVID-19 vaccine. Moderna, whose…
Headline
The American Medical Association yesterday announced Current Procedural Terminology codes for reporting the two-dose Novavax COVID-19 vaccine and its…
Headline
The Health Resources and Services Administration will provide nearly $1 billion to small rural hospitals, critical access hospitals and rural health clinics to…
Headline
Pfizer Inc. today said during its quarterly earnings call that it will file by the end of May for full Food and Drug Administration approval for its COVID-19…
Headline
The AHA today urged the Centers for Medicare & Medicaid Services to apply its recently increased Medicare payment rates for COVID-19 vaccine…